Urgent

Atopic keratoconjunctivitis (AKC)

Ocular allergy · Ophthalmology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic, perennial, bilateral ocular allergy (type IV with some type I) occurring mainly in adults with atopic dermatitis. Sight-threatening through corneal scarring, keratoconus and ulceration, so all suspected cases need ophthalmology. DRAFT for clinician review.

Red flags

  • Decreased vision
  • Corneal ulcer, thinning or perforation
  • Severe pain/photophobia
  • Herpetic keratitis (can complicate AKC and steroid use)
  • Retinal detachment symptoms (new floaters, flashes, curtain/black shadow)

Assessment

Differential diagnosis

  • Vernal keratoconjunctivitis (children, seasonal, upper tarsus)
  • Seasonal/perennial allergic conjunctivitis
  • Blepharitis
  • Ocular rosacea
  • Toxic conjunctivitis
  • Herpetic keratitis

Investigations

  • Clinical: perennial ocular itch + eyelid dermatitis + inferior-fornix/lower-tarsal papillary hypertrophy in a patient with atopic dermatitis
  • Slit-lamp examination by ophthalmology (cornea, bulbar and palpebral conjunctiva)
  • Fluorescein for corneal involvement
  • No established laboratory criteria

Management

  • Refer ALL suspected AKC to ophthalmology regardless of severity
  • Basic eye care: no eye rubbing, cool compresses, frequent refrigerated artificial tears
  • Topical dual-acting antihistamine/mast-cell stabiliser first-line
  • Brief topical corticosteroid pulse (ophthalmology) if inadequate response
  • Topical calcineurin inhibitor as steroid-sparing agent
  • Treat eyelid dermatitis (topical tacrolimus preferred)
  • Systemic agents / dupilumab for severe refractory disease

Drugs & doses

Topical dual-acting antihistamine/mast-cell stabiliser (first-line) — olopatadine, alcaftadine, bepotastine, azelastine, epinastine, ketotifen, or emedastine; twice daily (some once daily); full effect in 2–3 weeks.
Topical corticosteroid pulse (OPHTHALMOLOGIST) — mild–moderate: a 'soft' ester steroid, preferred loteprednol etabonate 0.5% twice daily × 2 weeks (or prednisolone acetate 0.12%, fluorometholone). Severe: prednisolone acetate 1% up to 8×/day for ~1 week, then reduce to 4×/day and taper. Avoid use >6 weeks.
Topical calcineurin inhibitor (steroid-sparing) — cyclosporine (prefer 2% compounded; 0.05–0.1% commercial available) or tacrolimus 0.03% for refractory/frequent-steroid cases.
Eyelid dermatitis — topical tacrolimus 0.1% (or pimecrolimus 1%) ointment, preferred over topical corticosteroid; low-potency fluorometholone/loteprednol ointment is an alternative (monitor ocular effects).
Oral nonsedating antihistamine (fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine) when topical therapy does not control itch.
Severe refractory (specialist) — oral cyclosporine 3–5 mg/kg/day or tacrolimus 0.03–0.08 mg/kg/day; dupilumab when AKC is driven by poorly controlled atopic dermatitis (baseline ophthalmic evaluation first — dupilumab-associated ocular surface disease risk).

Disposition

Refer all patients to ophthalmology (urgent if corneal involvement or vision change). Stable cases can be discharged on dual-acting drops and eyelid care with specialist follow-up.

Complications & pitfalls

  • Corneal scarring and chronic ulceration
  • Keratoconus (from persistent eye rubbing)
  • Corneal perforation
  • Cataract (disease- or steroid-related) and glaucoma
  • Herpetic keratitis
  • Retinal detachment
  • Vision loss

Exam pearls

  • Perennial itch + eyelid eczema + inferior-fornix/lower-lid papillae in an adult atopic = AKC
  • Unilateral disease should prompt another diagnosis (AKC is bilateral)
  • Refer all suspected AKC — corneal disease is easily missed without slit-lamp

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.